NuCana (NASDAQ:NCNA) Shares Down 1.5% – Time to Sell?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) traded down 1.5% during trading on Thursday . The stock traded as low as $1.31 and last traded at $1.33. 31,744 shares were traded during trading, a decline of 49% from the average session volume of 62,270 shares. The stock had previously closed at $1.35.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

NuCana Trading Down 1.5%

The stock’s fifty day moving average is $1.80 and its two-hundred day moving average is $2.17. The company has a market capitalization of $5.53 million, a PE ratio of -0.45 and a beta of 2.23.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $1.39.

Institutional Trading of NuCana

An institutional investor recently raised its stake in NuCana stock. FNY Investment Advisers LLC grew its position in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the period. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 at the end of the most recent quarter. Institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.